BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma

Summary

This is a prospective, single-arm, open-label, dose-finding and dose-expansion study that evaluates the safety, tolerability, PK, and anti-tumor efficacy of LCAR-BCDR cell preparations in relapsed/refractory multiple myeloma subjects who received adequate standard therapy.

Timeline

Start

2022-09-01

Primary completion

2025-05-27

Completion

2025-05-27

Outcome

Outcome not reported

Stopped: “Per sponsor request”

Drugs

Indications